These include genes associated with B-cell differentiation and development (18%; e.g., PAX5, IKZF1, EBF1), RAS signaling (48%; e.g., NRAS, KRAS, PTPN11, FLT3, NF1), JAK/STAT signaling (11%; e.g., JAK1, JAK2, IL7R, CRLF2), cell cycle regulation and tumor suppression (6%; e.g., TP53, RB1, CDKN2A/B), and non-canonical pathways or other/unknown genes (17%; e.g., CREBBP, NT5C2, TBL1XR1 [22,23]. This evidence concerns the gene CDKN2A and neoplasm.